Antibody Drug Conjugate Market : Understanding the Key Product Segments and Their Future by MRFR
Research Reports
Jan 05, 2021
Market Outlook
As per the records of WHO, in 2015, 15% of women were lost to breast cancer globally. Further, the increasing awareness about the treatment with antibody is propelling the market. In addition, the surging population is likely to play a vital role in magnifying the market. Besides, the development in the medical field is driving the market substantially. The increasing obese and geriatric population is estimated to escalate the market significantly during the forecast period.
According to Market Research Future (MRFR), the global antibody drug conjugate market is estimated to acquire a substantial market value, developing at a significant CAGR during the forecast period. It represents an innovative application that is an amalgamation of unique, high specificity, characteristics, and anti-tumor activity of monoclonal antibodies.
The global antibody drug conjugate market 2020 is rising at a swift pace owing to the rise in patient population battling cancer. The therapy can treat various types of cancer, such as breast cancer and endometrial cancer. Breast cancer is one of the most common forms of cancer attacking women.
On the contrary, the expensive cost of procedures, and the insufficient fund is projected to hamper the market growth. However, the increasing research and development initiatives, preclinical research, and the growing collaboration between research institutes is anticipated to combat the hampering factors.
Key Players
The renowned players of the global antibody drug conjugate market ImmunoGen, Inc. (US), Seattle Genetics (US), Roche Holding AG (Switzerland), Concortis Biotherapeutics (US), Genentech (US), Agensys, Inc. (US), Immunomedics (US), Antikor (UK), and Pfizer Inc. (US).
Regional Analysis
Based on the region, the global antibody drug conjugate market is segmented into America, Europe, Asia-Pacific, and the Middle East and Africa. As per the research, the global market is estimated to be commanded by the Americas due to technological innovation, development in the manufacturing method, and the participation of nanotechnology for developing Antibody Drug Conjugates (ADC). In the region, the US is recognized to acquire the largest market among other countries such as Canada and Mexico.
Europe is expected to acquire the second position. It is expected to be one of the most lucrative markets due to a large number of cancer patients in the region. Further, the participation of the government is estimated to fuel the market further.
Download the Free Sample PDF of Report:https://www.marketresearchfuture.com/sample_request/1113
The APAC region is projected to acquire a substantial market share during the forecast period. Countries like India and China are expected to be the fastest-growing region owing to the fast adoption of technology, larger population suffering from cancer, and the development of healthcare infrastructure.
The MEA region is estimated to procure the least amount of market share during the forecast period. The region is lagging owing to the presence of a poor economy. However, increasing awareness about health is likely to propel the market in the region.
Market Segmentation
The segment analysis of the global antibody drug conjugate market is based on type, product, technology, application, and end-user.
The type-based segments of the global antibody drug conjugate market are linker, drug/toxin, monoclonal antibodies, and others.
The product-based segments of the global antibody drug conjugate market are Kadcyla, Adcertis, and others.
Get Covid-19 Impact Analysis on “antibody drug conjugate market”:https://www.marketresearchfuture.com/enquiry/1113
The technology-based segments of the global antibody drug conjugate market are Seattle Genetics technology, ImmunoGen technology, Immunomedics technology, and others.
The application-based segments of the global antibody drug conjugate market are prostate cancer, leukemia, kidney cancer, ovary cancer, pancreas cancer, glioblastoma, colon cancer, lung cancer, breast cancer, solid tumors, skin cancer, multiple myeloma, lymphoma, and other cancers
Take Me to the Full Report:https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113
About Us:
Market Research Future (MRFR) is a world-renowned market research company that offers a wide range of services, complete with accurate and precise analysis about diverse markets, sub-markets and target consumers. Our approach is a combination of extensive information and multiple data sources that help provide an exhaustive comprehension about the latest major developments to the client, in addition to future events and what measures and decisions to take on the basis of the same.
Our fast emerging market research firm is armed with an adept research analysts’ team that focuses on gathering useful data and analytics in terms of economic and technological advances. Our proficient analysts conduct industrial visits in a bid to achieve reliable and accurate information from established market participants. One of our foremost objectives is to keep the client well-versed with all the lucrative opportunities as well as challenges surrounding various global markets. We offer step-by-step guidance to our clients, through consulting and strategic services, enabling them to arrive at a practical and effective decision.
Tags:
, Reportedtimes, Research Newswire, English